

# GW9662

Catalog No: tcsc1102



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

22978-25-2

**Formula:**

$C_{13}H_9ClN_2O_3$

**Pathway:**

Cell Cycle/DNA Damage

**Target:**

PPAR

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 100$  mg/mL (361.43 mM); H<sub>2</sub>O :

**Observed Molecular Weight:**

276.68


## Product Description

GW9662 is a potent and selective **PPAR $\gamma$**  antagonist with an **IC<sub>50</sub>** of 3.3 nM, showing 10 and 1000-fold selectivity over PPAR $\alpha$  and PPAR $\delta$ , respectively.

IC50 & Target: IC50: 3.3 nM/32 nM/2  $\mu$ M (PPAR $\gamma$ / $\alpha$ / $\delta$ )<sup>[1]</sup>

**In Vitro:** GW9662 inhibits radioligand binding to PPAR $\gamma$ , PPAR $\alpha$ , and PPAR $\delta$  with pIC<sub>50</sub>s of 8.48 $\pm$ 0.27 (IC<sub>50</sub>=3.3 nM; n=10), 7.49 $\pm$ 0.17 (IC<sub>50</sub>=32 nM; n=9), and 5.69 $\pm$ 0.17 (IC<sub>50</sub>=2000 nM; n=3), respectively. GW9662 has nanomolar IC<sub>50</sub> versus PPAR $\gamma$  and is 10- and 600-fold less potent in binding experiments using PPAR $\alpha$  and PPAR $\delta$ , respectively. In cell-based reporter assays, GW9662 is a potent and selective antagonist of full-length PPAR $\gamma$ <sup>[1]</sup>. Co-treatment with both 50  $\mu$ M Rosiglitazone and 10  $\mu$ M GW9662 results in statistically lower viable cell numbers after 7 days when compared to treatment with either 50  $\mu$ M rosiglitazone (P=0.001) or 10  $\mu$ M GW9662 (P=0.01) alone<sup>[2]</sup>.

**In Vivo:** Bone marrow (BM) nucleated cell counts in both BADGE- and GW9662(1 mg/kg, i.p.)-treated mice are significantly higher than counts in the aplastic anemia (AA) group<sup>[3]</sup>. GW9662 (1 mg/kg, i.p.) largely attenuates the renoprotective effects of Lipopolysaccharide (LPS) in the rat<sup>[4]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!